medigraphic.com

2010, Number 3

<< Back Next >>

Rev Fac Med UNAM 2010; 53 (3)

Tratamiento farmacológico de la fibromialgia: la experiencia de tres años

Cruz FL, Tamayo VAC, Guevara LU, Bautista EV

Language: Spanish
References: 67
Page: 11-18
PDF size: 304.03 Kb.


ABSTRACT

Objective: To present a three-year experience and treatment efficacy of fibromyalgia patients.
Material & methods: A retrospective, observational, longitudinal, and descriptive study of cases diagnosed and treated for fibromyalgia performed between October 2005 and September 2008. We included 18-year-old and older men and women diagnosed with fibromyalgia, using the patients’ pain intensity records according to the Analog Visual Scale (AVS), and accurate records of administered drugs and doses. Variables were studied using statistic analysis of central trend, standard deviation, variation coefficient, t-paired hypothesis and χ2 tests.
Results: 39 studied patients; female predominance (ratio 19.5:1); average age 57,2 years. Initial average for EVA 5,77 and final 4,95 (P‹.06); 14 patients (35,9%) with a low, 23 (59%) a medium and 2 (5,1%) a high EVA score. Nine patients (23,1%) had a low, 21 (53,8%) a medium and 9 (23,1%) a high variation coefficient. Used medication average was 4,56 and therapeutic scheme change was 7,15. More commonly prescribed medication was: tramadol, amitryptyline, paracetamol, gabapentine and pregabaline.
Conclusions: Fibromyalgia predominates in women older than 50. Pain is moderate most of the time. Most commonly used medication in our setting was: tramadol, amitryptyline, paracetamol, gabapentine and pregabaline. Depression is a frequent concomitant illness.


REFERENCES

  1. Abeles AM, Pillinger MH, Solitary BM, et al. Narrative Review: The Pathophysiology of Fibromyalgia. Ann Intern Med. 2007;146:726-34.

  2. Shipley M. Fibromyalgia. Medicine. 2002;4:81-4.

  3. Wolfe F, Symthe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160-72.

  4. Villanueva VL, Valia JC, Cerda G, et al. Fibromialgia: diagnóstico y tratamiento. El estado de la cuestión. Rev Soc Esp Dolor. 2004;11:430-43.

  5. Clauw DJ. Fibromyalgia: historical perspective. Dynamic Chiropractic. 2000;18:14-27.

  6. Hernández NL, Guevara U. Características del dolor en las pacientes diagnosticadas con fibromialgia.

  7. Tovar MA. Fibromialgia. Col Med. 2005;36:287-91.

  8. Staud R. Biology and therapy of fibromyalgia: pain in fibromialgia syndrome. Arthr ResTher. 2006;8:208-15.

  9. Merayo LA, Cano FJ, Rodríguez L, et al. Un acercamiento bibliométrico a la investigación en fibromialgia. Reumatol Clin. 2007;3:55-62.

  10. 10.- Barrera MI, Cortes JF, Guerrero H, et al. La fibromialgia: ¿Un síndrome somático funcional o una nueva conceptualización de la histeria? Análisis cuali-cuantitativo. Salud Mental. 2005;28:41-50.

  11. Gamez L. ¿Existe realmente la fibromialgia reumática? Una reflexión personal. Rev Mex Neuroci. 2006;7:354.

  12. Canoso JJ. Fibromialgia ¿Una enfermedad reumatológica? Rev Mex Reumat. 2002; 17:113-6.

  13. Alegre C. Reflexiones sobre fibromialgia y la utilidad de elaborar un documento de consenso por su diagnóstico y tratamiento. Reumatol Clin. 2006;1:S1.

  14. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. ArthritisRheum. 1995;38:19-22.

  15. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778-85.

  16. Yunus MB, Inanici F, Aldag JC, Mangold RF. Fibromyalgia in men: comparison of clinical features with women. J Rheumatol. 2000;27:485-94.

  17. Valverde M. Prevalencia de la fibromialgia en la población española. Estudio EPISER. Rev Esp Reumatol. 2000;27:157-68.

  18. Clark P. Frecuencia y características de la fibromialgia en el Hospital General de México: revisión de la epidemiología. Rev Mex Reumat. 2001;16:191-7.

  19. Vidal LF. Síndrome de fibromialgia: diagnóstico y manejo. Rev Soc Per Med Inter. 2003;16:22-30.

  20. Meléndez C, Zaa M. Síndrome de fibromialgia. Epidemiología. Centro de Medicina Física y Rehabilitación “Dr. Regulo Carpio López”. Barquisimeto. Estado Lara. Enero 1998-Noviembre 2003. Bol Med Post. 2005;21:1-7.

  21. Sarró S. Fibromialgia reumática: aspectos psiquiátricos. Actas Esp Psiquiatr. 2002;30:392-6.

  22. Raphael KG, Janal MN, Nayak S, et al. Familial aggregation of depression in fibromyalgia: a community-based test of alternate hypotheses. Pain. 2004;110:449-60.

  23. Sherman JJ, Turk DC y Okifufuji A. Prevalence and Impact of Posttraumatic Stress Disorder-Like Symptoms on Patients With Fibromyalgia Syndrome. Clin J Pain. 2000;16:127-34.

  24. Banic B, Petersen S, Andersen OK, et al. Evidence for spinal cord hypersensitivity in chronic pain after whiplash injury and in fibromyalgia. Pain. 2004;107:7-15.

  25. Ruiz M, Nadador V, Fernández J, et al. Dolor de origen muscular: dolor miofascial y fibromialgia. Rev Soc Esp Dolor. 2007;1:36-44.

  26. Skinner CM, Flores MS, Colunga IJ, et al. Enfermedad de Lyme. Medicina Universitaria. 2007;9:24-32.

  27. García FJ, Lao JI, Beyer K, et al. Relación entre genotipos del gen catecol O-metiltransferasa y la gravedad de la fibromialgia. Reumatol Clin. 2006;2:168-72.

  28. Rivera J, Alegre C, Ballina FJ, et al. Documento de consenso de la Sociedad Española de Reumatología sobre la fibromialgia. Reumatol Clin. 2006;2(supl 1):S55-S66.

  29. Buskila D, Sarzi P, Soroka H, et al. Fibromialgia y enfermedades autoinmunes. IMAJ. 2008;10:77-83

  30. Alonso Carmen, Loevinger BL, Muller D, et al. Menstrual cycle influences on pain and emotion in women with fibromyalgia. J Psychosomatic Res 2004; 57:451-458

  31. Rodríguez E, Díaz C, Guinot M, et al. Disfunción tiroidea en mujeres con sospecha de fibromialgia. Reumatol Clin. 2006;2:70-7.

  32. Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromialgia. Mayo Clin Proc. 1999;74:385-98.

  33. Martínez M. Un acercamiento “holístico” al enigma de la fibromialgia: la disautonomía. Rev Mex Reumat. 2002;17:237-40.

  34. Julien N, Goffauxb P, Arsenalultb P, et al. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 2005;114:295-302.

  35. Vierck CJ. Mechanisms underlying development of spatially distributed chronic pain (fibromyalgia). Pain. 2006;124:242-63.

  36. 36.- Staud R, Koo E, Robinson E, et al. Spatial summation of mechanically evoked muscle pain and painful aftersensations in normal subjects and fibromyalgia patients. Pain. 20007;130:177-87.

  37. Staud R, Bovee CE, Robinson ME, et al. Cutaneous C-fiber pain abnormalities of fibromyalgia patients are specifically related to temporal summation. Pain In press.

  38. Sim J, Madden S. Illness experience in fibromyalgia syndrome: A metasynthesis of qualitative studies. Social Science & Medicine. 2008;67:57-67.

  39. Martínez E, González O, Crespo JM. Fibromialgia: definición, aspectos clínicos, psicológicos, psiquiátricos y terapéuticos. Salud mental. 2003;4:1-9.

  40. González JI, García M. Síndromes de dolor miofascial y fibromialgia. Anestesia en México. 2005;17:1-7.

  41. Aréchiga G. Fibromialgia: una enfermedad silenciosa. Anestesia en México. 2004;16:1-9.

  42. Arnold L, Keck P, Welge JA. Antidepressant Treatment of Fibromyalgia. A Meta-Analysis and Review. Psychosomatics. 2000;41:104-13.

  43. Heymann RE, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clin Exp Rheumatol. 2001;19:697-705.

  44. Arnold LM. Biology and therapy of fibromialgia. New therapies in fibromialgia. Arthritis Research & Therapy. 2006; 8:212-32.

  45. Nishishinya B, Urrútia G, Rodriguez A, et al. Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology. 2008;47:1741-8.

  46. Abeles M, BM Solitar, Pillinger MH, et al. Update on Fibromyalgia Therapy. Am J Med. 2008;121:555-61.

  47. Ozerbil O, Okudan N, Gokbel H, Levendoglu F. Comparison of the effects of two antidepressants on exercise performance of the female patients with fibromyalgia. Clin Rheumatol. 2006;25:495-503.

  48. Arnold LM, Rosenb A, Pritchettb YL, et al. A randomized, double-blind, placebo controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5-15.

  49. Arnold LM, Pritchett YL, Rosen AS, et al. Duloxetine in the Treatment of Fibromyalgia in Women - Results from two Clinical Trials. Annals of the Rheumatic Diseases. 2005;64:S230-7.

  50. Arnold LM, Pritchett YL, D’Souza DN, et al. Duloxetine for the Treatment of Fibromyalgia in Women. J Womens Health. 2007;16:1145-51.

  51. Arnold LA, Pritchett Y, D’Souza DD, et al. An Evaulation of the Safety and Efficacy of Duloxetine in the Treatment of Women with Fibromylgia Syndrome: Results from two Clinical Studies. Annals of the Rheumatic Diseases. 2007;66(Suppl 2):422-8.

  52. Sultan A, Gaskell H, Darry Sheena, et al. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology. 2008;8:29-38.

  53. Russell IJ, Mease PJ, Smith TR. Efficacy and safety of duloxetine for treatment of fibromialgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136:432-41.

  54. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, doubleblind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264-73.

  55. Crofford LJ, Simpson S, Young JP, et al. A six-month, double-blind, placebo-controlled, durability of effect study of pregabalin for pain associated with fibromyalgia. Arthritis Rheum. 2006;54:4118-28.

  56. Calandre EP, Morillas-Arques P, Rodriguez-Lopez CM, et al. Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label, prospective trial. Pharmacopsychiatry. 2007;40:68-75.

  57. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durabilityof meaningful relief (FREEDOM): A 6-month, double-blind, placebocontrolled trial with pregabalin. Pain. 2008;136:419-31.

  58. Mease PJ, Russell IJ, Arnold LM. A Randomized, Doubleblind, Placebo-Controlled, Phase III Trial of Pregabalin in the Treatment of Patients with Fibromyalgia. J Rheumatol First Release. 2008;35:1-13.

  59. Abud M, Moreno R, Wade C, et al. Gabapentina (Gp): una herramienta útil en el tratamiento del dolor en pacientes con fibromialgia (FM). Informe preliminar. Rev Mex Reumat. 2001;16:367-71.

  60. Acin MP, Escartin R. Gabapentina en el tratamiento de la fibromialgia. Rev Soc Esp dolor. 2005;12:211-6.

  61. Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double- blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56:1336-42.

  62. Biasi G, Manca S, Manganelli S, et al. Tramadol in the fibromyalgia syndrome: A controlled clinical trial versus placebo. Int J Clin Pharmacol Res. 1998;18:13-20.

  63. Bennett R, Kamin M, Rosenthal N, et al. Efficacy and Safety of a Tramadol/Acetaminophen Combination (Ultracet(tm)) in the Management of Fibromyalgia Related Pain: a Multicenter, Outpatient, Randomized, Double-blind, Placebocontrolled Study. Arthritis & Rheumatism. 2001;44:S67-76.

  64. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebocontrolled study. Am J Med. 2003;114:537-45.

  65. Bennett RM, Schein J, Kosinski MR, et al. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum. 2005;53:519-27.

  66. Gur A, Calgan N, Nas K, et al. Low Dose of Tramadol in the Treatment of Fibromyalgia Syndrome: a Controlled Clinical Trial Versus Placebo. Annals of the Rheumatic Diseases. 2006;65(Suppl 2):556-61.




2020     |     www.medigraphic.com